Patients with stage IV non–small-cell lung cancer (NSCLC) and BRAF V600 mutations may benefit from targeted therapies.
The French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study was a national prospective cohort study aiming to describe the molecular characteristics and clinical outcome of all consecutive NSCLC patients screened for molecular alterations
83 cases with BRAF mutant disease were matched to 166 controls. Five cases received tyrosine kinase inhibition in the first-line and 16 in the second-line. All others were treated with standard chemotherapy. There was no significant difference in first-line and second-line progression-free survival (PFS) between the groups, as well as in the disease control rate, BRAF mutation was not found to be prognostic of overall survival. We found no significant difference in outcome between the treatment types used in first-line or second-line in patients with BRAF-MT disease compared with controls nor between BRAF V600E or non-V600E compared with controls.
BRAF mutation is not a strong prognostic factor in NSCLC.
https://www.ejcancer.com/article/S0959-8049(19)30270-9/pdf
